search
Back to results

Serotonin Control of Impulsivity in Tourette Disorder (ARITEP)

Primary Purpose

Tourette Disorder

Status
Not yet recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Administration of a PET radiotracer
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tourette Disorder focused on measuring Tourette, Serotonin, Impulsivity, Neuroimaging

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria * : Male or Female Diagnosed with a Tourette Disorder following the DSM-5 Age between 18-65 years Member of a social security scheme in France Freely-given informed consent to participate to this study (written form) With a current treatment by aripiprazole already scheduled With Tics compatible with TEP/fMRI exams Having (for women only) effective contraception throughout participation in the study. Exclusion Criteria * : Male or Female A serious not controlled psychiatric comorbidity A serious, evolving or debilitating pathology with a potential influence on the study Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin) Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia) Women breastfeeding Protected or restricted person (administratively or in judicial terms) Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study Do not speak french

Sites / Locations

  • Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
  • Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Tourette disorder

Arm Description

20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.

Outcomes

Primary Outcome Measures

Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.

Secondary Outcome Measures

Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.
Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.
Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.

Full Information

First Posted
July 4, 2023
Last Updated
July 12, 2023
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT05942716
Brief Title
Serotonin Control of Impulsivity in Tourette Disorder
Acronym
ARITEP
Official Title
Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 1, 2026 (Anticipated)
Study Completion Date
September 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tourette Disorder
Keywords
Tourette, Serotonin, Impulsivity, Neuroimaging

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tourette disorder
Arm Type
Experimental
Arm Description
20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.
Intervention Type
Drug
Intervention Name(s)
Administration of a PET radiotracer
Intervention Description
A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.
Primary Outcome Measure Information:
Title
Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).
Description
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.
Time Frame
As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Secondary Outcome Measure Information:
Title
Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.
Description
Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.
Time Frame
As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Title
Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).
Description
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.
Time Frame
As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Title
Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.
Description
Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.
Time Frame
As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria * : Male or Female Diagnosed with a Tourette Disorder following the DSM-5 Age between 18-65 years Member of a social security scheme in France Freely-given informed consent to participate to this study (written form) With a current treatment by aripiprazole already scheduled With Tics compatible with TEP/fMRI exams Having (for women only) effective contraception throughout participation in the study. Exclusion Criteria * : Male or Female A serious not controlled psychiatric comorbidity A serious, evolving or debilitating pathology with a potential influence on the study Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin) Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia) Women breastfeeding Protected or restricted person (administratively or in judicial terms) Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study Do not speak french
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin PASQUEREAU
Phone
+33 437 911 241
Email
benjamin.pasquereau@isc.cnrs.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Stephane THOBOIS
Phone
+33 472 357 222
Email
stephane.thobois@chu-lyon.fr
Facility Information:
Facility Name
Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephane THOBOIS, MD
Facility Name
Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yulia WORBE, MD
Phone
+33 142 161 316
Email
yworbe@gmail.com

12. IPD Sharing Statement

Learn more about this trial

Serotonin Control of Impulsivity in Tourette Disorder

We'll reach out to this number within 24 hrs